New Drugs for HDL-C Disorders: The Beginning
MyNgan Duong and Stephen J. NichollsAffiliation:
South Australian Health and Medical Research Institute. PO Box 11060. Adelaide, SA, 5001, Australia.
AbstractFor more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.
Atherosclerosis, cardiovascular disease, HDL, lipids, risk factors.
Purchase Online Order Reprints Order Eprints Rights and Permissions